One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Baseline eGFR at or below 45: generally not recommended unless benefit exceeds risk; this population was not studied. If treatment is chosen despite severe impairment, the reduced starting dose is 15.8 mg twice daily.
RDM32-voclosporin-lupkynis-1 · Source locator: 2.4; 8.6
Monitor eGFR every 2 weeks in month 1, every 4 weeks through year 1, then quarterly.
If eGFR is below 60 and falls more than 20% but less than 30% from baseline, reduce each twice-daily dose by 7.9 mg. Recheck within 2 weeks; if the fall remains above 20%, reduce again by 7.9 mg twice daily.
If eGFR is below 60 and the fall is at least 30%, discontinue. Recheck within 2 weeks; consider restarting 7.9 mg twice daily only after recovery to at least 80% of baseline. After a renal-driven reduction, consider increasing by 7.9 mg twice daily for each measurement at least 80% of baseline, without exceeding the starting dose.
RDM32-voclosporin-lupkynis-2 · Source locator: 2.3
Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.
Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=voclosporin-lupkynis&s1=RDM32-label-voclosporin-lupkynis&h1=86eb1ebc47cfeb446c14103a2d1f4acb5ddd38577922f79ee622e6057bb4c89e